Breaking Finance News

RBC Capital announced Insys Therapeutics (NASDAQ:INSY), dropping its stock price target to $26.00 today

In a statement issued on 09/22/2016 RBC Capital bumped down the target of Insys Therapeutics (NASDAQ:INSY) from $32.00 to $26.00 indicating a possible upside of 0.96%.

Just yesterday Insys Therapeutics (NASDAQ:INSY) traded -3.49% lower at $13.27. Insys Therapeutics’s 50-day moving average is $15.76 and its 200-day moving average is $15.32. The last stock price is down -13.35% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,191,965 shares of INSY traded, up from an avg. trading volume of 811,777

See Chart Below

Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics has a 52 week low of $11.45 and a 52 week high of $33.88 with a P/E ratio of 19.98 The company’s market cap is currently $0.

In addition to RBC Capital reporting its stock price target, a total of 5 analysts have released a research note on Insys Therapeutics. The 12-month target is $24.40 with 1 broker rating the stock a strong buy, 3 firms rating the company a buy, one brokerage rating the company a hold, zero analysts rating the company a underperform, and lastly 0 firms rating the company a sell.

Brief Synopsis About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *